REPORT ID 2489

China Hemoglobinopathies Drugs Market Research Report 2017

Publish Date
8-Dec-17
Pages
111
Format
Electronic (PDF)

The global Hemoglobinopathies Drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Hemoglobinopathies Drugs development status and future trend in China, focuses on top players in China, also splits Hemoglobinopathies Drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
    Gamida Cell
    Alnylam Pharmaceuticals
    Biogen Idec
    Sangamo BioSciences Inc.
    Genetix Pharmaceuticals/Bluebird Bio
    Global Blood Therapeutics Inc.
    Pfizer Inc.
    Mast Therapeutics
    Emmaus Life Sciences, Inc.
    Prolong Pharmaceuticals
    Celgene Corporation
    HemaQuest Pharmaceuticals

Geographically, this report splits the China market into six regions,
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
    Thalassemia Therapy
    Sickle Cell Disease(SCD) Therapy
    Other Therapy

On the basis of the end users/application, this report covers
    Alpha Thalassemia
    Beta thalassemia
    Sickle Cell Disease
    Hb Variants Diseases

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

China Hemoglobinopathies Drugs Market Research Report 2017
1 Hemoglobinopathies Drugs Overview
    1.1 Product Overview and Scope of Hemoglobinopathies Drugs
    1.2 Classification of Hemoglobinopathies Drugs by Product Category
        1.2.1 China Hemoglobinopathies Drugs Sales (K Pcs) Comparison by Type (2012-2022)
        1.2.2 China Hemoglobinopathies Drugs Sales (K Pcs) Market Share by Type in 2016
        1.2.3 Thalassemia Therapy
        1.2.4 Sickle Cell Disease(SCD) Therapy
        1.2.5 Other Therapy
    1.3 China Hemoglobinopathies Drugs Market by Application/End Users
        1.3.1 China Hemoglobinopathies Drugs Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Alpha Thalassemia
        1.3.3 Beta thalassemia
        1.3.4 Sickle Cell Disease
        1.3.5 Hb Variants Diseases
    1.4 China Hemoglobinopathies Drugs Market by Region
        1.4.1 China Hemoglobinopathies Drugs Market Size (Million USD) Comparison by Region (2012-2022)
        1.4.2 South China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
        1.4.3 East China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
        1.4.4 Southwest China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
        1.4.5 Northeast China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
        1.4.6 North China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
        1.4.7 Central China Hemoglobinopathies Drugs Status and Prospect (2012-2022)
    1.5 China Market Size (Sales and Revenue) of Hemoglobinopathies Drugs (2012-2022)
        1.5.1 China Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (%)(2012-2022)
        1.5.2 China Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 China Hemoglobinopathies Drugs Market Competition by Players/Manufacturers
    2.1 China Hemoglobinopathies Drugs Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2 China Hemoglobinopathies Drugs Revenue and Share by Players/Manufacturers (2012-2017)
    2.3 China Hemoglobinopathies Drugs Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.4 China Hemoglobinopathies Drugs Market Competitive Situation and Trends
        2.4.1 China Hemoglobinopathies Drugs Market Concentration Rate
        2.4.2 China Hemoglobinopathies Drugs Market Share of Top 3 and Top 5 Players/Manufacturers
        2.4.3 Mergers & Acquisitions, Expansion in China Market
    2.5 China Players/Manufacturers Hemoglobinopathies Drugs Manufacturing Base Distribution, Sales Area, Product Types

3 China Hemoglobinopathies Drugs Sales and Revenue by Region (2012-2017)
    3.1 China Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
    3.2 China Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
    3.3 China Hemoglobinopathies Drugs Price (USD/Pcs) by Regions (2012-2017)

4 China "&B1&" Sales and Revenue by Type/ Product Category (2012-2017)"
    4.1 China Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
    4.2 China Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
    4.3 China Hemoglobinopathies Drugs Price (USD/Pcs) by Type (2012-2017)
    4.4 China Hemoglobinopathies Drugs Sales Growth Rate (%) by Type (2012-2017)

5 China "&B1&" Sales by Application (2012-2017)"
    5.1 China Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
    5.2 China Hemoglobinopathies Drugs Sales Growth Rate (%) by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6 China Hemoglobinopathies Drugs Players/Suppliers Profiles and Sales Data
    6.1 Gamida Cell
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Gamida Cell Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Alnylam Pharmaceuticals
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Biogen Idec
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biogen Idec Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Sangamo BioSciences Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Genetix Pharmaceuticals/Bluebird Bio
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Global Blood Therapeutics Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Pfizer Inc.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Mast Therapeutics
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Emmaus Life Sciences, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Prolong Pharmaceuticals
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Hemoglobinopathies Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Celgene Corporation
    6.12 HemaQuest Pharmaceuticals

7 Hemoglobinopathies Drugs Manufacturing Cost Analysis
    7.1 Hemoglobinopathies Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Hemoglobinopathies Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Hemoglobinopathies Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Hemoglobinopathies Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 China Hemoglobinopathies Drugs Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 China Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    11.2 China Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Type (2017-2022)
    11.3 China Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Application (2017-2022)
    11.4 China Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List